Morgans just added this ASX 100 blue-chip stock to its "conviction buy" list

The market weakness won't last and Morgans thinks this is a great opportunity to load up on quality stocks starting with those on its S&P/ASX 100 (Index:^ATOI) (ASX: XTO) conviction list.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed (Resmed Inc (ASX:RMD)) share price is waning this morning as the sleep disorder treatment device maker tries to regain favour with the market.

ResMed's share price fell 0.9% to $14.68 in late morning trade as the S&P/ASX 200 (Index:^AXJO) (ASX: XJO) index eased 0.2%.

Its shares are down nearly 9% since October as growth stocks on high price-earnings (P/E) multiples have lost favour with investors amid rising US government bond yields and worries that these market darlings have run ahead of fundamentals.

The company has managed to recover from some of its steeper losses since it posted a credible first quarter result on October 26 but questions remain if the stock can retest its record high of $16.04 that it hit at the start of last month.

Morgans thinks it can and has just added ResMed to its "high conviction" stock list and has offered three reasons for investors to buy the stock.

"The company remains well positioned, in our view, with continued growth across masks and devices, a solid pipeline of new products and an expanding digital platform helping to drive resupply, low setup costs and improve adherence rates," said the broker.

"1Q results were above expectations, driven by the fifth straight quarter of double-digit sales growth, an expanding product range, stable GMs and strength in the company's leading connected-care offerings."

Thirdly, there's still plenty of growth left ahead for ResMed. Morgans noted that 12 million Americans suffer from sleep apnoea (based on statistics from the US National Heart Blood and Lung Institute) but ResMed said less than four million are diagnosed or treated each year – and that's only for the US.

Morgans has a $16.40 price target on the stock.

But ResMed isn't the only S&P/ASX 100 (Index:^ATOI) (ASX: XTO) stock on Morgans' conviction list. Copper miner OZ Minerals Limited (ASX: OZL), plumbing products group Reliance Worldwide Corporation Ltd (ASX: RWC) and our second largest mortgage lender Westpac Banking Corp (ASX: WBC) are also on the list.

Coincidentally, OZ Minerals share price is surging 2.3% at the time of writing to $9.47 thanks to stronger copper prices overnight and bullish market sentiment towards the mining sector.

On the flipside, Westpac's share price is struggling to keep its head above breakeven after the bank handed in its full-year profit report card, while Reliance Worldwide's share price is down 1.5% at $5.11.

Looking for other blue-chips to put on your watchlist? The experts at the Motley Fool have picked three of their best blue-chip stock ideas for FY19 and you can find out what these are for free by following the link below.

Motley Fool contributor Brendon Lau owns shares of Reliance Worldwide Limited and Westpac Banking. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cheap Shares

An older man wearing glasses and a pink shirt sits back on his lounge with his hands behind his head and blowing air out of his cheeks.
Cheap Shares

Down 40%: Is this cheap ASX 200 share a buy after its bombshell news?

Goldman Sachs thinks a total return of 30% is possible for investors from this stock.

Read more »

a man holds his arms out and shrugs his shoulders as if indicating he doesn't know the answer to a question he's been asked.
Cheap Shares

Down 40%! Should you buy this beaten down ASX 200 stock?

One leading broker has given its verdict on this sold-off stock.

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Cheap Shares

Where to invest $10,000 in a bullish share market?

High share prices shouldn't dissuade you from investing in the markets.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy
Cheap Shares

This ASX 300 stock is trading with the widest discount in its history

Bell Potter thinks this stock could be dirt cheap.

Read more »

a man with a wide, eager smile on his face holds up three fingers.
Cheap Shares

Here are my top 3 undervalued ASX shares to buy right now

These stocks are excellent picks in my opinion.

Read more »

Three cute kids with mixed expressions poke their heads out from the back of a kombi.
Cheap Shares

Three ASX shares down 10% to 23%! Are they cheap?

Price doesn't equal value.

Read more »

Smiling couple looking at a phone at a bargain opportunity.
Cheap Shares

History says these 3 ASX shares are dirt cheap today

These beaten-down ASX shares could be offering great value for money.

Read more »

Woman looking at her smartphone and analysing share price.
Cheap Shares

Why this ASX All Ords stock is 'extremely undervalued' right now

This expert is calling the market's cheapest stock.

Read more »